{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:00Z","timestamp":1786979940700,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"This work was supported by the Doctor Foundation of the First Affiliated Hospital of Harbin Medical University","award":["Grant 2023B15"],"award-info":[{"award-number":["Grant 2023B15"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06653-y","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:39:39Z","timestamp":1766021979000},"page":"6197-6204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of venetoclax-azacitidine combined with low-dose Idarubicin and cytarabine regimens for the treatment of newly diagnosed acute myeloid leukemia patients compared to the standard chemotherapy: a propensity score-matched real-world single-center experience"],"prefix":"10.1007","volume":"104","author":[{"given":"Xiao-Tong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Qiu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Jin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"10393","key":"6653_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD et al (2023) Acute myeloid leukaemia. Lancet 401(10393):2073\u20132086. https:\/\/doi.org\/10.1016\/S0140-6736(23)00108-3","journal-title":"Lancet"},{"issue":"11","key":"6653_CR2","doi-asserted-by":"publisher","first-page":"e805","DOI":"10.1016\/S2352-3026(24)00274-6","volume":"11","author":"MA Perusini","year":"2024","unstructured":"Perusini MA, Yee KWL (2024) Transplantation and long-term overall survival in acute myeloid leukaemia. Lancet Haematol 11(11):e805\u2013e806. https:\/\/doi.org\/10.1016\/S2352-3026(24)00274-6","journal-title":"Lancet Haematol"},{"issue":"9","key":"6653_CR3","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1158\/1078-0432.CCR-23-3673","volume":"30","author":"A Bazarbachi","year":"2024","unstructured":"Bazarbachi A, Labopin M, Moukalled N et al (2024) Improvements in posttransplant outcomes over two decades in older patients with acute myeloid leukemia in the EBMT ALWP study. Clin Cancer Res 30(9):1778\u20131787. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3673","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6653_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3322\/caac.21873","volume":"75","author":"HM Kantarjian","year":"2025","unstructured":"Kantarjian HM, DiNardo CD, Kadia TM (2025) Acute myeloid leukemia management and research in 2025. CA Cancer J Clin 75(1):46\u201367. https:\/\/doi.org\/10.3322\/caac.21873","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"6653_CR5","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","volume":"361","author":"HF Fernandez","year":"2009","unstructured":"Fernandez HF, Sun Z, Yao X et al (2009) Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361(13):1249\u20131259","journal-title":"N Engl J Med"},{"issue":"8","key":"6653_CR6","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1182\/blood-2010-03-273243","volume":"117","author":"S Ohtake","year":"2011","unstructured":"Ohtake S, Miyawaki S, Fujita H et al (2011) Randomized study of induction therapy comparing standard-dose Idarubicin with high-dose Daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 study. Blood 117(8):2358\u20132365","journal-title":"Blood"},{"issue":"25","key":"6653_CR7","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","volume":"125","author":"AK Burnett","year":"2015","unstructured":"Burnett AK, Russell NH, Hills RK et al (2015) A randomized comparison of Daunorubicin 90\u00a0mg\/m2 vs 60\u00a0mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 125(25):3878\u20133885","journal-title":"Blood"},{"issue":"7","key":"6653_CR8","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1200\/JCO.1992.10.7.1103","volume":"10","author":"WR Vogler","year":"1992","unstructured":"Vogler WR, Velez-Garcia E, Weiner RS et al (1992) A phase III trial comparing Idarubicin and Daunorubicin in combination with cytarabine in acute myelogenous leukemia: a southeastern cancer study group study. J Clin Oncol 10(7):1103\u20131111. https:\/\/doi.org\/10.1200\/JCO.1992.10.7.1103","journal-title":"J Clin Oncol"},{"issue":"7","key":"6653_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"issue":"5","key":"6653_CR10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1507471","volume":"374","author":"A Ivey","year":"2016","unstructured":"Ivey A, Hills RK, Simpson MA et al (2016) Assessment of minimal residual disease in standard-risk AML. N Engl J Med 374(5):422\u2013433","journal-title":"N Engl J Med"},{"issue":"8","key":"6653_CR11","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1200\/JCO.21.01546","volume":"40","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, Jonas BA, Pullarkat V et al (2022) Measurable residual disease response and prognosis in treatment-naive acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol 40(8):855\u2013865","journal-title":"J Clin Oncol"},{"issue":"12","key":"6653_CR12","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ, Zhou S, Fu C et al (2020) Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol 6(12):1890\u20131899","journal-title":"JAMA Oncol"},{"issue":"5","key":"6653_CR13","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1016\/S2352-3026(22)00076-X","volume":"9","author":"CA Lachowiez","year":"2022","unstructured":"Lachowiez CA, Reville PK, Kantarjian H et al (2022) Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol 9(5):e350\u2013e360. https:\/\/doi.org\/10.1016\/S2352-3026(22)00076-X","journal-title":"Lancet Haematol"},{"issue":"3","key":"6653_CR14","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/bjh.18709","volume":"201","author":"H Wang","year":"2023","unstructured":"Wang H, Yao Y, Mao L et al (2023) Venetoclax plus \u20182\u2009+\u20095\u2019 modified intensive chemotherapy with Daunorubicin and cytarabine in fit elderly patients with untreated de Novo acute myeloid leukaemia: a single-centre retrospective analysis. Br J Haematol 201(3):568\u2013572. https:\/\/doi.org\/10.1111\/bjh.18709","journal-title":"Br J Haematol"},{"issue":"8","key":"6653_CR15","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","volume":"8","author":"TM Kadia","year":"2021","unstructured":"Kadia TM, Reville PK, Borthakur G et al (2021) Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or adverse-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol 8(8):e552\u2013e561. https:\/\/doi.org\/10.1016\/S2352-3026(21)00192-7","journal-title":"Lancet Haematol"},{"issue":"25","key":"6653_CR16","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1200\/JCO.20.03736","volume":"39","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Lachowiez CA, Takahashi K (2021) Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol 39(25):2768\u20132778. https:\/\/doi.org\/10.1200\/JCO.20.03736","journal-title":"J Clin Oncol"},{"issue":"6","key":"6653_CR17","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","volume":"9","author":"H Wang","year":"2022","unstructured":"Wang H, Mao L, Yang M et al (2022) Venetoclax plus 3\u2009+\u20097 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol 9(6):e415\u2013e424. https:\/\/doi.org\/10.1016\/S2352-3026(22)00106-5","journal-title":"Lancet Haematol"},{"issue":"12","key":"6653_CR18","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"6653_CR19","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) (2017) v5.0. National Cancer Institute; https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"issue":"1","key":"6653_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01269-x","volume":"15","author":"C Willekens","year":"2025","unstructured":"Willekens C, Bazinet A, Chraibi S et al (2025) Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. Blood Cancer J (1):68. https:\/\/doi.org\/10.1038\/s41408-025-01269-x","journal-title":"Blood Cancer J"},{"issue":"2","key":"6653_CR21","doi-asserted-by":"publisher","first-page":"E63","DOI":"10.1002\/ajh.27180","volume":"99","author":"O Karrar","year":"2024","unstructured":"Karrar O, Abdelmagid M, Rana M et al (2024) Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: comparative analysis of response, toxicity, and survival. Am J Hematol 99(2):E63\u2013E66. https:\/\/doi.org\/10.1002\/ajh.27180","journal-title":"Am J Hematol"},{"issue":"1","key":"6653_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01270-4","volume":"3","author":"N Gangat","year":"2025","unstructured":"Gangat N, Tefferi A (2025) Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days. Blood Cancer J 3(1):56. https:\/\/doi.org\/10.1038\/s41408-025-01270-4","journal-title":"Blood Cancer J"},{"key":"6653_CR23","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ et al (2021) 2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD working party. Blood 138:2753\u20132767. https:\/\/doi.org\/10.1182\/blood.2021013626","journal-title":"Blood"},{"issue":"1","key":"6653_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41408-024-00976-1","volume":"14","author":"Y Cao","year":"2024","unstructured":"Cao Y, Huo W, Huang J et al (2024) MRD positivity was the poor prognostic factor for adverse-risk AML patients with allogeneic hematopoietic stem cell transplantation: a multicenter TROPHY study. Blood Cancer J 14(1):8. https:\/\/doi.org\/10.1038\/s41408-024-00976-1","journal-title":"Blood Cancer J"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06653-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06653-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06653-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:15:18Z","timestamp":1767485718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06653-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6653"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06653-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6258400\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}